2744. A Phase I Randomized, Observer-Blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (Laboratory Code, FB-631) Co-administered with Seasonal TIV (2013–2014) to Healthy Adults ≥18–50 Years of Age

BACKGROUND: Inactivated influenza vaccines (IV) efficacy is variable and sometimes poor. In this phase 1 trial the safety and immunogenicity of a novel nanoparticle adjuvant (Papaya Mosaic Virus (PapMV or PAL) at different dose levels combined with inactivated trivalent IV (TIV; FLUVIRAL® 2013–2014,...

Descripción completa

Detalles Bibliográficos
Autores principales: Langley, Joanne Marie, Pastural, Elodie, Halperin, Scott, McNeil, Shelly, ElSherif, May, MacKinnon-Cameron, Donna, Ye, Lingyun, Lapointe, Rejean, McElhaney, Janet, Martin, Luis, Bolduc, Marilène, Laliberté-Gagné, Marie-Ève, LeClerc, Denis, Savard, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809641/
http://dx.doi.org/10.1093/ofid/ofz360.2421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809641/
http://dx.doi.org/10.1093/ofid/ofz360.2421

Ejemplares similares